SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current conventional histological scoring system, in quantifying treatment-associated changes in Nonalcoholic Steatohepatitis (NASH). AI-DP with Second Harmonic Generation/Two-photon Excitation Fluorescence (SHG/TPEF) was employed in the FLIGHT-FXR study (NCT02855164) to gather a deeper understanding of fibrosis dynamics in the overall liver biopsy, in different zones within the liver lobules and its colocalized spatial relation to changes in steatosis and hepatocyte ballooning in patients with non-cirrhotic NASH who were treated with Tropifexor (TXR). Findings from the 48-week study were recently published in the online issue of the Journal of Hepatology.
Results of the FLIGHT-FXR study showed that the AI-based qFibrosis highlighted treatment-associated regression of overall liver fibrosis, as well as marked regression in perisinusoidal fibrosis in patients with either significant fibrosis (F2) or advanced fibrosis (F3) at baseline. A concomitant zonal quantification of the fibrosis and steatosis parameters using qFibrosis and qSteatosis revealed that patients with greater qSteatosis reduction also have the greatest reduction in perisinusoidal fibrosis. This shows that hepatic lipid load reduction, as a result of anti-metabolic treatment, drives fibrosis regression initially in the perisinusoidal regions.
Says Professor Nikolai Naoumov MD, PhD, Advisor in Digital Pathology, Drug Development and Research in Liver Diseases, and principal author of the study, "SHG AI-based platform is able to quantify precisely fibrosis changes while avoiding variations caused by staining, and provides novel insights in treatment-induced fibrosis regression, which are not captured by current staging systems. In addition, quantifying changes in steatosis and hepatocyte ballooning concomitantly in a colocalized spatial environment demonstrated the direct association between improvement in the metabolic activity of NAFLD with fibrosis regression. This SHG approach has demonstrated great potential for clinical trial investigators to understand treatment efficacy and disease mechanisms of NASH."
Adding to this is Professor Arun Sanyal, Professor of the Internal Medicine Department, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University, and co-author of the study states "This work demonstrates that SHG imaging and automated digital analytics can not only assist pathologists evaluate changes in liver histology in a more granular and accurate way but also provides novel insights on the evolution of fibrosis and changes in fibrosis upon initiation of therapy. These have important implications for drug development and the way treatment responses are assessed in phase 2B and 3 trials".
Founded in Singapore, HistoIndex is a leading MedTech/Healthcare company that specializes in its proprietary integrated stain-free AI digital pathology platform. Enabled by Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE) along with automated imaging analysis algorithms, the integrated platform accurately quantifies histological features and fine measurements that are critical for the evaluation of therapeutic efficacy in clinical trials. The stain-free AI platform is currently involved in multiple FDA clinical trials for Nonalcoholic Steatohepatitis (NASH). In addition, it has benefitted more than 150 research and academic institutes, CROs and biopharma companies around the world in drug discovery and development efforts for fibrotic diseases and cancers.
ReferencesDigital pathology with artificial intelligence analyses provides greater insights into treatment induced fibrosis regression in NASH
Naoumov NV, Brees D, Loeffler J, Chng E, Ren Y, Lopez P, Tai D, Lamle S, Sanyal AJ. Journal of Hepatology (2022), doi: https://doi.org/10.1016/j.jhep.2022.06.018.
View original content:https://www.prnewswire.com/news-releases/histoindex-stain-free-ai-dp-reveals-treatment-induced-zonal-regression-of-fibrosis-colocalized-with-reduction-in-steatosis--hepatocyte-ballooning-in-flight-fxr-nash-clinical-trial-301596019.html
- Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
- Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss
- Molecular Stethoscope, Inc. announces new investment from the Alzheimer's Drug Discovery Foundation
- Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
- Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
- Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
- New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
- Covid-19 patient with liver cancer dies
- Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection